A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly-Reference-Cited by-同舟云学术

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly

Published:2009-09-07 Issue:4 Volume:71 Page:549-557
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:

Author:

Trainer Peter J.,Ezzat Shereen,D’Souza Gwyn A.,Layton Gary,Strasburger Christian J.

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2265.2009.03620.x/fullpdf

Reference24 articles.

1. AACE medical guidelines for clinical practice for the diagnosis and treatment of acromegaly;AACE Acromegaly Guidelines Task Force;Endocrine Practice,2004

2. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly;Swearingen;Journal of Clinical Endocrinology and Metabolism,1998

3. Factors influencing mortality in acromegaly;Holdaway;Journal of Clinical Endocrinology and Metabolism,2004

4. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance;Colao;European Journal of Endocrinology,2006

5. Somatostatin analogs in acromegaly;Freda;Journal of Clinical Endocrinology and Metabolism,2002

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults;Cochrane Database of Systematic Reviews;2024-02-06

2. Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP);Annales d'Endocrinologie;2023-12

3. Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly;Archives of Medical Research;2023-12

4. Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience;Journal of Endocrinological Investigation;2023-03-09

5. Self-reported symptoms in patients with acromegaly: a 6-month follow-up in a single neurosurgical center;Endocrine Journal;2023